Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2024 results
Roche 2024 results Basel, 30 January 2025
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: Performance Outlook
Performance Outlook
Slide 6: 2024: Strong business performance in both divisions
2024: Strong business performance in both divisions FY results all at CER • Group sales growth +7%; base business growth: +9% Group, +9% Pharma and +8% Diagnostics • COVID-19 sales decreased by CHF -1.1bn in line with guidance, and LOE impact was CHF -1.0bn • Core OP growth +14%, Group core OP margi
Slide 7: 2024 guidance exceeded
2024 guidance exceeded Group sales achieved at upper end of guidance and Core EPS exceeds guidance raised at HY Guidance Results Group sales growth1 Mid single digit sales growth +7% High single digit Core EPS growth +12% Core EPS growth1 excl. impact from resolution of tax (+7% incl. impact from re
Slide 8: 2024: Dividend per share increased to CHF 9.70
2024: Dividend per share increased to CHF 9.70 38th year of consecutive dividend increase 9.701 CAGR +11.8% 1989 1994 1999 2004 2009 2014 2019 2024 12024 dividend as proposed by the Board of Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary i
Slide 9: 2024: Group sales growth at +7% with base business at +9%
2024: Group sales growth at +7% with base business at +9% Both divisions with continued strong momentum; no COVID-19 impact going forward 2024 2023 Change in % Excl. CHFbn CHFbn CHF CER C191 Pharmaceuticals Division 46.2 44.3 4 8 9 Diagnostics Division 14.3 14.5 -1 4 8 Roche Group 60.5 58.7 3 7 9 1B
Slide 10: 2024: Continued strong growth momentum
2024: Continued strong growth momentum Consistent high single-digit growth achieved in the last three quarters Group sales growth Group base business sales growth1 %CER %CER +15% +15% +11% +10% +9% +9% +9% +9% +10% +9% +9% +8% +7% +5% +5% +2% +2% +3% +3% +1% +1% 0% 0% -3% COVID-19 Pandemic COVID-19
Slide 11: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio 17 medicines achieved blockbuster status in 20241 Diagnostics: +8% base business growth +4% FY 2024 sales driven by Core Lab, Molecular Lab and (+8%)2 (CHFbn, YoY CER growth) Pathology Lab Phesgo: Conversion rate climbing to 46% 14.3 Alecensa: Geographic exp
Slide 12: Performance Outlook
Performance Outlook
Slide 13: Overview of key strategic initiatives
Overview of key strategic initiatives Strategic review completed and in implementation Ten-Year Ambitions Group Strategy Group Strategy Digital Health Sustainability People & Culture Pharma Strategy Diagnostics Strategy Divisional Strategies R&D Excellence Formation of Near Patient Care Operational
Slide 14: Comprehensive platform strategy in Near Patient Care
Comprehensive platform strategy in Near Patient Care Accu-Chek® LumiraDx cobas® liat cobas® vital cobas® sense SmartGuide CGM • Multimodal technology • 14 day real-time glucose • Lab equivalent PCR testing • Reliable and sustainable • Lab equivalent (clinical chemistry, sensor at the PoC BGE platfor
Slide 15: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term Two NMEs launched in 2024: Itovebi in HR+ BC and PiaSky in PNH CHFm % of Pharma Sales2 30.0 56% 25.0 51% 44% 20.0 35% 15.0 1 10.0 5.0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.0 FY 2021 FY 2022 FY 2023 FY 2024 Cotellic Alecensa
Slide 16: 2025 Pharma pipeline
2025 Pharma pipeline Peak sales potential of key assets New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME/UME Itovebi (inavolisib) Elevidys1 CT-388 Pi3Km BC DMD Obesity +/- T2D • 7+ NMEs with CHF >3bn peak divarasib GYM 329 CT-868 KRAS+ NSCLC, CRC SMA, FSHD T1D w
Slide 17: 2025 Pharma pipeline
2025 Pharma pipeline 12 key pivotal readouts including 4 NMEs expected New Molecular Entities (NME) 2 giredestrant Ph III persevERA 2 fenebrutinib Ph III FENhance 1/2 1 vamikibart Ph III HR+ BC Ph III evERA RMS, PPMS Ph III FENtrepid DME/UME SANDCAT/MEERKAT Itovebi (inavolisib) Elevidys CT-388 Pi3Km
Slide 18: 2025 Pharma pipeline
2025 Pharma pipeline 7 NMEs with Ph III enabling readouts expected New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME/UME Itovebi (inavolisib) Elevidys CT-388 Pi3Km BC DMD Obesity +/- T2D divarasib GYM 329 CT-868 KRAS+ NSCLC, CRC SMA, FSHD T1D with BMI ≥25 tiragol
Slide 19: 2025 guidance
2025 guidance LOE impact of CHF 1.2bn expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1At CER=Constant Exchange Rates (avg full year 2024); LOE=loss of exclusivity includ
Slide 20: Finance
Finance Alan Hippe Chief Financial Officer
Slide 21: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 22: 2024: Group performance
2024: Group performance Sales increase of +7% and Core EPS increase of +7% (+12% excl. 2023 resolution of tax disputes) 2024 2023 Change in % CHFm CHFm CHF CER Sales 60,495 58,716 3 7 Core operating profit 20,823 19,240 8 14 as % of sales 34.4 32.8 Core net income 16,011 15,804 1 7 as % of sales 26.
Slide 23: 2024: Group sales growth
2024: Group sales growth Base business growth exceeds COVID-19 and LOE impact CHFm +7% at CER -522 -952 +5,078 -2,328 +1,055 -552 58,716 60,495 FY 2023 Dia Dia Pharma Ronapreve LOE Fx FY 2024 base COVID-19 (excl. Ronapreve, sales business sales LOE) Base business=Pharma excluding Ronapreve and Diagn
Slide 24: 2024: Group core operating profit
2024: Group core operating profit Core operating profit higher by +14% driven by higher sales and effective cost management 2024 2024 vs. 2023 CHFm abs. CER CER growth Sales 60,495 +4,107 7% Other revenue 1,900 +215 12% Cost of sales -15,398 -720 5% R&D -13,042 -128 1% SG&A -13,758 -625 5% OOI&E 626
Slide 25: 2024: Core operating profit and margin
2024: Core operating profit and margin 45.7% 47.7% % of sales +2.1%p¹ 32.8% 34.4% +2.1%p¹ +13%¹ CHFm +14%¹ 16.7% 16.8% 22,014 20,823 20,240 +1.3%p¹ 19,240 +12%¹ 2,417 2,402 2023 2024 Roche Group Pharma Division Diagnostics Division Note: Group Core operating profit includes -3.6bn from Corporate (-3
Slide 26: 2024: Core net financial result
2024: Core net financial result Decrease mainly driven by increased interest expenses CHFm • Net financial result decreased by -394m / +31% at CER • Interest expenses1 increased by 442m / +55% at CER -1,300 -1,610 +67 +28 -413 +8 FY 2023 Equity Net interest Interest Other FY 2024 securities income e
Slide 27: 2024: Core tax rate
2024: Core tax rate Tax rate up due to the higher impact from resolution of tax disputes in 2023 and Pillar Two top-up tax in 2024 +4.8%p Impact from resolution of tax disputes Effective tax rate excl. impact from Pillar Two top-up tax and resolution of tax disputes Impact of Pillar Two top-up tax +
Slide 28: 2024: Core EPS development
2024: Core EPS development Core EPS driven by operations growth partially offset by higher interest expenses, taxes & lower product disposals +12.4% + 17.4%p - 1.1%p 20.26 - 2.3%p - 1.2%p - 0.4%p 18.99 -0.97 18.02 FY 2023 Effects of FY 2023 Operations1 Product disposals Financial Tax rate change All
Slide 29: 2024: Non-core and IFRS income
2024: Non-core and IFRS income Non-core operating expenses higher vs. PY mainly due to higher goodwill impairments of CHF 3.2bn 2023 2024 Var. Change in % CHFm CHFm at CER CHF CER Core operating profit 19,240 20,823 +2,684 +8 +14 Global restructuring plans -2,038 -1,891 +126 Amortisation of intangib
Slide 30: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 31: 2024: Group operating free cash flow
2024: Group operating free cash flow OFCF up by +34% driven by higher cash operating profit, and favorable NWC movement +2,187 CHFm +76 +878 -594 +1,309 -1,092 +3,713 21,213 20,121 15,831 OFCF up by +34%/+5,382m at CER FYstart 2023 Op netOP, net ofadjustment of cash cashNTWCNTWC Other Other movement
Slide 32: 2024: Operating free cash flow and margin
2024: Operating free cash flow and margin 48.3% 40.8% % of sales +7.4%p¹ 33.3% 26.9% +6.8%p¹ 9.3% 12.1% +28%¹ +34%¹ +3.9%p¹ 22,288 20,121 CHFm 18,055 15,768 +48%¹ 1,350 1,734 2023 2024 Roche Group Pharma Division Diagnostics Division Note: Group Operating free cash flow includes -3.9bn from Corporat
Slide 33: 2024: Group net debt development
2024: Group net debt development Net debt lower by CHF 1.4bn vs. YE 2023 Free Cash Flow CHF +15.3 [PY: +11.3] CHFbn [PY: -15.6] [PY: +15.8] [PY: -4.5] [PY: -14.4] [PY: -18.7] -4.8 Taxes -3.7 Treasury -1.1 Dividends paid -8.0 M&A & All. trans. -3.1 Curr. Transl. & Oth. -1.7 Trans. own eq. inst. -1.1
Slide 34: Balance sheet 31 December 2024
Balance sheet 31 December 2024 Equity ratio at 36% (31 Dec 2023: 37%) % change in CER % change in CER vs 31 Dec 2023 vs 31 Dec 2023 CHFbn 101.8 +10% 101.8 +10% Cash and 90.5 17.3 90.5 marketable +65% 27.0 10.5 17% +6% securities 12% 27% Current 24.8 22.7 -3% 27% Other 23.0 liabilities 22% current 25
Slide 35: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 36: 2024: Currency impact and outlook
2024: Currency impact and outlook USD / CHF In 2024 impact1 is (%p): -6% -3% -2% -2% 0.93 Q1 Q2 Q3 Q4 0.91 0.90 0.90 Sales -8 -2 -3 -3 0.87 0.89 0.88 0.88 Q1 HY Sep FY 0.86 0.88 0.89 0.91 0.91 0.89 0.89 0.86 0.85 0.86 0.88 0.89 YTD Monthly avg fx rates 2024 Average YTD 2024 Average YTD 2023 Sales -8
Slide 37: 2024: Core EPS
2024: Core EPS Core EPS 2024 of CHF 19.33 is basis for Core EPS outlook 2025 at CER CHF 19.33 18.80 +0.53 Core EPS 2024 2024 foreign Core EPS 2024 basis as reported exchange losses: for outlook Core EPS Core EPS impact growth 2025 at CER CER=Constant Exchange Rates 37
Slide 38: 2025 guidance
2025 guidance LOE impact of CHF 1.2bn expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1At CER=Constant Exchange Rates (avg full year 2024); LOE=loss of exclusivity includ
Slide 39: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 40: 2024: Pharmaceuticals sales
2024: Pharmaceuticals sales Strong growth in US, EU and International 2024 2023 Change in % CER w/o CHFm CHFm CHF CER Ronapreve Pharmaceuticals Division 46,171 44,265 4 8 9 United States 24,774 23,259 7 9 9 Europe 8,832 8,306 6 8 8 Japan 2,874 3,745 -23 -16 -2 International 9,691 8,955 8 17 17 CER=C
Slide 41: 2024: Pharmaceuticals core operating profit
2024: Pharmaceuticals core operating profit Core operating profit higher by +13%, driven by higher sales and effective cost management 2024 2024 vs. 2023 CHFm abs. CER CER growth Sales 46,171 +3,604 8% Other revenue 1,871 +263 16% Cost of sales -8,457 -640 8% R&D -11,096 -98 1% SG&A -7,036 -319 5% O
Slide 42: 2024: Young portfolio delivering strong growth
2024: Young portfolio delivering strong growth Polivy now one of 17 blockbusters in 2024* Vabysmo 68% Phesgo 62% Ocrevus 9% Hemlibra 12% Xolair 16% Polivy 39% Evrysdi 18% Elevidys n/a Columvi >500% Gazyva 16% Actemra / RoActemra 5% Alecensa 7% Enspryng 30% Xofluza 75% Perjeta 1% Tecentriq 0% US Luns
Slide 43: Itovebi EU approval expected in H1 2025
Oncology/Hematology Itovebi EU approval expected in H1 2025 Phesgo conversion rate climbing to 46% in 55 launch countries* Itovebi Q4 update CHFm 8 / N/A Others • Phesgo: Strong uptake across all regions CHFm 671 / -9% Avastin • Perjeta: Phesgo conversion ongoing CHFm 1,233 / -17% Tecentriq CHFm 3,6
Slide 44: Polivy US patient share in 1L DLBCL reaching 29%
Oncology/Hematology Polivy US patient share in 1L DLBCL (IPI 0-5) reaching 29% Bi-specifics moving into 2L DLBCL: Columvi (STARGLO) approval and Lunsumio Ph III (SUNMO) readout in 2025 Q4 update Lunsumio Columvi CHFm 71 / +25% • Hemlibra: Strong Q4 growth across all regions and pts segments CHFm 172
Slide 45: Hematology: Portfolio further strengthened by allogeneic CAR-Ts
Oncology/Hematology Hematology: Portfolio further strengthened by allogeneic CAR-Ts Moving into autoimmune diseases including MS and SLE Roche/Poseida allogeneic CAR-Ts key features Allogeneic CAR-T pipeline Robust healthy donor screening system Development Molecule TA Indication status Non-viral ge
Slide 46: Ocrevus Zunovo (SC) launched with high share of naive patients
Neurology Ocrevus Zunovo (SC) launched with high share of naive patients Elevidys Ph III (EMBARK) 2-year data reinforce functional benefit and will be shared with regulators Q4 update Elevidys • Ocrevus: #1 new to brand in US; Zunovo with >2,500 patients CHFm 189 / N/A Others CHFm 392 / +5% worldwid
Slide 47: Elevidys providing clinically meaningful benefits in DMD
Neurology Elevidys providing clinically meaningful benefits in DMD Ph III (EMBARK) 2-year data reinforce sustained functional benefit and will be shared with regulators Ph III (EMBARK) Part 1 two-year data* Key development projects Endpoint Elevidys EC LSMean difference (95% CI) p-value Ph I Ph II P
Slide 48: Parkinson's Disease: Prasinezumab next steps to be determined in 2025
Neurology Parkinson’s Disease: Prasinezumab next steps to be determined in 2025 Ph IIb (PADOVA) prasinezumab missed primary endpoint, but suggests possible clinical benefit Prasinezumab (α-synuclein Ab) Ph IIb (PADOVA) trial design Placebo IV Q4W Open-label extension Prasinezumab IV Q4W Randomise (1
Slide 49: Xolair with strong launch uptake in food allergy
Immunology Xolair with strong launch uptake in food allergy US/EU filings for Gazyva in lupus nephritis submitted, approvals expected in 2025 Q4 update • Xolair: Strong food allergy launch with 40k patients on treatment Others CHFm 951 / -7% • Additional growth driven by strong CSU performance • No
Slide 50: Anti-TL1A: Expanding the development program beyond IBD
Immunology Anti-TL1A: Expanding the development program beyond IBD RG6631 with best-in-disease potential in IBD; Additional trials in atopic dermatitis and MASH to initiate in Q1 2025 Anti-TL1A implicated in inflammatory and fibrotic processes1,2 RG6631 (anti-TL1A) development program DR3 Receptor D
Slide 51: Vabysmo US market share expansion in nAMD, DME and RVO continues
Ophthalmology Vabysmo US market share expansion in nAMD, DME and RVO continues Vabysmo pre-filled syringe approved in EU, with US reaching >85% conversion Q4 update Luxturna CHFm 18 / -59% Susvimo • Vabysmo: Continued market share gains across early launch Lucentis CHFm 4 / +44% countries and ongoin
Slide 52: Strengthening our Pharma pipeline: Two deals closed since Q3
Strengthening our Pharma pipeline: Two deals closed since Q3 Pipeline changes since Q2’23 siRNA targeting AGT in Allogeneic CAR-T in hypertension Onco/Heme, Immuno and Neuro 8 -8 24 Additions 81 4 -3 1 -5 • 14 Ph I additions from 3 -4 3 pRED/gRED/Chugai -9 5 -5 71 • 10 Ph I/Ph II NMEs acquired as Du
Slide 53: 2024: Key newsflow
2024: Key newsflow* Compound Indication Milestone Alecensa Adjuvant ALK+ NSCLC US/EU approval Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC US/EU filing Tecentriq Subcutaneous administration US/EU approval PiaSky (crovalimab) PNH US/EU approval Elevidys DMD EU filing Ocrevus 6m SC RMS/PPM
Slide 54: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval Lunsumio SC 3L+ FL US approval/EU filing (EU filing) Elevidys DMD EU approval Regulatory Gazyva Lupus nephritis US/EU fili
Slide 55: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 56: 2024: Diagnostics sales
2024: Diagnostics sales Strong base business growth more than offsetting decline in COVID-19 sales 2024 2023 Change in % Excl. CHFm CHFm CHF CER C191 Diagnostics Division 14,324 14,451 -1 4 8 Core Lab 8,004 7,750 3 8 Molecular Lab 2,590 2,567 1 4 Near Patient Care 2,167 2,746 -21 -17 Pathology Lab 1
Slide 57: 2024: Diagnostics highlights
2024: Diagnostics highlights Strong base business growth more than offsetting decline in COVID-19 sales CHFbn YoY CER growth Core Lab • Immunodiagnostics (+9%) +8% • Clinical Chemistry (+8%) • COVID-19 (-60%) Molecular Lab +4% • Virology base business (+10%) • Blood Screening (+17%) Near Patient • C
Slide 58: 2024: Diagnostics regional sales
2024: Diagnostics regional sales North America +6% EMEA ~30% of divisional sales +5% ~34% of divisional sales Asia Pacific Latin America -5% +22% ~29% of divisional sales ~7% of divisional sales Base business=excluding COVID-19-related products; Growth rates at Constant Exchange Rates (avg full year
Slide 59: 2024: Diagnostics core operating profit
2024: Diagnostics core operating profit Strong core operating profit growth of +12% 2024 2024 vs. 2023 CHFm abs. CER CER growth Sales 14,324 +503 4% Other revenue 29 -47 -61% Cost of sales -6,941 -79 1% R&D -1,946 -30 2% SG&A -3,136 -90 3% OOI&E 72 +16 27% Core operating profit 2,402 +273 12% Core O
Slide 60: cobas Mass Spectrometry solution
Core Lab cobas® Mass Spectrometry solution CE mark for the first fully integrated IVD platform for clinical mass spectrometry cobas® Mass Spectrometry solution Market opportunity • The current total mass spectrometry market is CHF 3bn, primarily composed of laboratory developed tests1 • Roche Diagno
Slide 61: cobas 6800/8800 version 2.0
Molecular Lab cobas® 6800/8800 version 2.0 CE mark for the updated systems with increased testing flexibility, higher throughput and automation cobas® 6800/8800 version 2.0 Market needs and opportunity • Extend competitive differentiation of installed base, fully compatible with existing menu and ne
Slide 62: Clinical study results for Elecsys Amyloid Plasma Panel
Core Lab Clinical study results for Elecsys®Amyloid Plasma Panel Strong rule out performance (NPV > 90%) in a prospective multicenter study Elecsys® Amyloid Plasma Panel testing Unmet need • >55 million people live with Alzheimer’s disease, 75% of people experiencing symptoms remain undiagnosed1 Ele
Slide 63: Diagnostics key launches 2024
Diagnostics key launches 2024 Area Product Description Markets Status i601 mass spectrometry Launch of an unique total solution for clinical mass spectrometry testing: fully automated, integrated and CE system IVD-compliant Core Lab cobas® c703 Introducing high-throughput clinical chemistry testing
Slide 64: Diagnostics key launches 2025
Diagnostics key launches 2025 Area Product Description Market Status Elecsys® pTau181 Non-invasive blood-based biomarker to enable earlier detection and rule out amyloid pathology CE Elecsys® high-sensitivity High-sensitive test with greater precision at lower measurement ranges, enabling HCPs to co
Slide 65: Invitation to Roche Diagnostics upcoming IR events
Invitation to Roche Diagnostics upcoming IR events Innovating Diagnostics, shaping healthcare, changing lives Update on sequencing technology Roche Diagnostics Day 20 Feb 2025 27 May 2025 Virtual event London / hybrid event Sequencing by Expansion (SBX) Technology Highlights: • Roche Sequencing solu
Slide 66: Upcoming IR events
Upcoming IR events
Slide 67: IR events currently planned for 2025
IR events currently planned for 2025 Additional events driven by readouts Immunology/WCN Update on NGS Neurology Update Diagnostics Day Pharma Day 7 Feb 20 Feb 4 Apr 27 May 22 Sep 16:30 – 17:30 CET tbd 16:00 – 17:30 CEST 14:00 - 16:30 CEST tbd Virtual event Virtual event Virtual event London & virtu
Slide 68: Appendix contents: pipeline, sales and FX information
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 69: Changes to the development pipeline
Changes to the development pipeline Q4 2024 update New to phase I New to phase II New to phase III New to registration 5 NMEs: 2 AIs: RGXXXX* P-MUC1C-ALLO1 – solid tumors RG7159 Gazyva - lupus nephritis RG6810 DLL3 ADC – SCLC RG7828 Lunsumio SC - 3L+ FL RG6620 KRAS G12D inhibitor - solid tumors RG65
Slide 70: Roche Group development pipeline
Roche Group development pipeline Phase I (46 NMEs + 7 AIs) Phase II (15 NMEs + 6 AIs) RG6026 Columvi monotherapy + combos heme tumors CHU codrituzumab HCC RG6107 PiaSky sickle cell disease RG6076 englumafusp alfa combos heme tumors CHU CD137 switch solid tumors RG6171 giredestrant endometrial cancer
Slide 71: Roche Group development pipeline
Roche Group development pipeline Phase III (8 NMEs + 30 AIs) Registration US & EU (2 NME + 8 AIs) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD RG6026 Columvi + chemo 2L+ DLBCL Columvi + Polivy + R-CHP 1L DLBCL RG6299 sefaxersen (ASO factor B) IgA nephropathy Itovebi (inavolisib) +
Slide 72: Expected regulatory submissions
Expected regulatory submissions* New Molecular Entities: Lead and additional indications anti-latent myostatin RG6237 (GYM 329) + Evrysdi SMA New Molecular Entity (NME) Cardiovascular, Renal & Metabolism anti-latent myostatin Additional Indication (AI) Neurology giredestrant RG6237 (GYM 329) RG6171
Slide 73: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism Additional Indication (AI) Neurology Oncology / Hematology Ophthalmology Immunology Other PiaSky RG6107 ✓ Indicates submission to health authorities has occurred s
Slide 74: Major pending approvals 2024
Major pending approvals 2024 US EU China Japan-Chugai TNKase Itovebi (inavolisib) + palbociclib + Ocrevus Tecentriq fulvestrant RG1594 RMS & PPMS RG7446 Alveolar Soft Part Sarcoma RG3625 stroke RG6114 1L HR+ PIK3CA-mut. mBC Filed March 2024 Filed Jan 2024 Filed June 2023 Filed April 2024 Itovebi (in
Slide 75: Major granted approvals 2024
Major granted approvals 2024 US EU China Japan-Chugai Xolair Tecentriq SC PiaSky PiaSky RG3648 Food allergy RG7446 all approved indications RG6107 PNH RG6107 PNH Feb 2024 Jan 2024 Feb 2024 March 2024 Alecensa Alecensa Vabysmo Vabysmo RG7853 ALK+ NSCLC adj RG7853 ALK+ NSCLC adj RG7716 BRVO/CRVO RG771
Slide 76: Doing now what patients need next
Doing now what patients need next